A detailed history of Calamos Advisors LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Calamos Advisors LLC holds 32,349 shares of HALO stock, worth $1.53 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
32,349
Previous 43,968 26.43%
Holding current value
$1.53 Million
Previous $2.3 Million 19.64%
% of portfolio
0.01%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$51.3 - $64.42 $596,054 - $748,495
-11,619 Reduced 26.43%
32,349 $1.85 Million
Q2 2024

Jul 25, 2024

BUY
$37.81 - $52.4 $1.66 Million - $2.3 Million
43,968 New
43,968 $2.3 Million
Q4 2022

Jan 25, 2023

SELL
$40.06 - $59.44 $508,641 - $754,709
-12,697 Reduced 40.89%
18,354 $0
Q3 2022

Oct 24, 2022

SELL
$38.53 - $51.78 $2.68 Million - $3.61 Million
-69,673 Reduced 69.17%
31,051 $1.23 Million
Q2 2022

Aug 01, 2022

BUY
$37.35 - $48.3 $3.76 Million - $4.86 Million
100,724 New
100,724 $4.43 Million
Q2 2021

Jul 22, 2021

SELL
$38.84 - $51.31 $2.5 Million - $3.3 Million
-64,359 Closed
0 $0
Q1 2021

Apr 12, 2021

SELL
$39.51 - $51.45 $2.11 Million - $2.75 Million
-53,357 Reduced 45.33%
64,359 $2.68 Million
Q4 2020

Jan 27, 2021

BUY
$25.81 - $43.62 $556,076 - $939,792
21,545 Added 22.4%
117,716 $5.03 Million
Q3 2020

Oct 26, 2020

BUY
$25.74 - $29.63 $1.27 Million - $1.47 Million
49,468 Added 105.92%
96,171 $2.53 Million
Q2 2020

Jul 27, 2020

BUY
$16.25 - $26.81 $758,923 - $1.25 Million
46,703 New
46,703 $1.25 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.57B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Calamos Advisors LLC Portfolio

Follow Calamos Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Advisors LLC with notifications on news.